

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): January 12, 2015

---

**SECOND SIGHT MEDICAL PRODUCTS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

**California**

(State or Other Jurisdiction of Incorporation)

---

**333-198073**

(Commission File Number)

---

**02-0692322**

(IRS Employer Identification No.)

**12744 San Fernando Road, Building 3  
Sylmar, California 91342**

(Address of Principal Executive Offices)

---

**(818) 833-5000**

(Registrant's Telephone Number, Including Area Code)

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 7.01. REGULATION FD DISCLOSURE**

A copy of a slide presentation that Second Sight Medical Products, Inc. ("Second Sight ") will use during presentations made before individuals and small groups at the JP Morgan 33<sup>rd</sup> Annual Healthcare Conference, January 12, 2015 through January 15, 2015 (the "Presentation Materials"), is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. Additionally, Second Sight has posted the Presentation Materials on the Investor Relations section of Second Sight's website: <http://investors.secondsight.com>. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits

**Exhibit No. Description**

99.1 Second Sight Medical Products, Inc. Investor Presentation dated January 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**SECOND SIGHT MEDICAL PRODUCTS, INC.**

By: /s/ Thomas B. Miller  
By: Thomas B. Miller  
Chief Financial Officer

Date: January 12, 2015



## **Investor Presentation**

NASDAQ: EYES

**January 2015**

# Forward Looking Statements

Nasdaq: EYES



This presentation contains certain forward-looking information about Second Sight that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "strong," "up coming," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance.

In this document, we refer to information regarding potential markets for products and other industry data. We believe that all such information has been obtained from reliable sources that are customarily relied upon by companies in our industry. However, we have not independently verified any such information.

2

Forward-looking statements may address the following subjects among others: expected products, applications, customers, technologies and performance, coverage and insurance reimbursements, results of clinical studies, success of research and development and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties referred to in the risk factors section of the final prospectus filed with the Securities and Exchange Commission relating to our Registration Statement on Form S-1 for our IPO. The audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.





CNN Video: 'Bionic eye' lets blind man 'see' again




<http://edition.cnn.com/video/data/2.0/video/international/2014/06/18/spc-vital-signs-roger-pontz-bionic-eye.cnn.html>

**Second Sight's Purpose:** Restoring vision to the blind





YouTube Video: First Implant at Duke Eye Center



<https://www.youtube.com/watch?v=CiyGOUHD2nI>

**Second Sight's Purpose:** Restoring vision to the blind





- Restoring vision to the blind with the Argus II platform technology
- Targeting significant addressable market of over 8 million people
- Commercial stage – FDA, Canada, EU, & Turkey regulatory approvals
- Strong financial position –
  - Successful IPO in November 2014 raised \$36.2M total gross.
  - Company is debt free
- Shares outstanding –
  - Total shares outstanding: 35.3M
  - Fully diluted shares including options and warrants: 39.6M






**39 million people worldwide are legally blind**

8 million patients globally are legally blind due to unpreventable causes

## Second Sight's Global Addressable Markets

*(# individuals worldwide)*



6

# The Argus® II System – A 25 Year Journey

Argus II Glasses

Video Processing Unit (VPU)

Argus II Implant



60 electrodes

1. Miniature video camera captures scene

3. System bypasses dead photoreceptors and stimulates underlying neurons

1

2

3

4

2. Communication to VPU and to implant

4. Processes video and transforms into instructions for implant

# Experienced Management and Board

Nasdaq: EYES



## Decades of Experience Creating Value from Disruptive Technology


<b>Robert Greenberg</b>	<b>Alfred E. Mann</b>
<i>President, Chief Executive Officer &amp; Director</i>	<i>Chairman of the Board of Directors &amp; Founder</i>
<ul style="list-style-type: none"> <li>• Co-managed the Alfred E. Mann Foundation</li> <li>• Served as lead reviewer for IDEs and 510(k)s at the Office of Device Evaluation at FDA</li> </ul>	<ul style="list-style-type: none"> <li>• Directs MannKind Corporation</li> <li>• Served as CEO of MiniMed (acquired by Medtronic) and Pacesetter Systems; Co-CEO of Advanced Bionics Corporation</li> </ul>

8

<b>William J. Link</b>	<b>Aaron Mendelsohn</b>	<b>Gregg Williams</b>
<i>Director</i>	<i>Director &amp; Founder</i>	<i>Director</i>
<ul style="list-style-type: none"> <li>• Co-founder and managing director of Versant Ventures</li> <li>• Founded and served as Chairman and CEO of Chiron Vision</li> <li>• Experienced ophthalmology investor</li> </ul>	<ul style="list-style-type: none"> <li>• Served on the board of Advanced Bionics</li> <li>• Founder and director of MRG, sold to Medtronic</li> </ul>	<ul style="list-style-type: none"> <li>• CEO of Williams International Corporation</li> <li>• Director of General Aviation Manufacturers Association</li> </ul>

# Drivers of Mass Adoption


Nasdaq: EYES



9

# R&D and Regulatory Milestones

Nasdaq: EYES





## Resolution enhancement without adding electrodes

---

- Controlling the relative stimulation applied to adjacent electrodes can produce spatial patterns of stimulation between electrodes (“virtual electrodes”)
- Potential resolution enhancement: 10x – 100x at the pixel level
- Large body of work to draw upon in cochlear implant technology
- Capital efficient path to resolution enhancement
- Key variables:
  - Relative pulse amplitude in adjacent electrodes
  - Pulse shape
  - Pulse duration

11

*From Bonham and Litvak, “Current Focusing and Steering,” Hearing Research 242 (2008), 141-153.*



Preliminary data indicates Argus II may be an effective treatment for AMD

---

**Experimental work conducted in Armand Tanguay Jr.'s lab at USC indicated simulations with retinal prostheses in AMD patients may:**

- Improve time to grasp a target object and ability to avoid obstacles to grasping a target
- Improve functional depth task performance
- Allow blind patients to perform daily tasks with more ease, accuracy, and speed

12

**Human experiments at Johns Hopkins produced phosphenes in two AMD patients**




The Orion I visual prosthesis – low development risk, 5 million+ patients

---

**Objective: bypass the optic nerve and directly stimulate the visual cortex**

**Risks mitigated:**

- Orion I requires relatively minor modifications to the Argus II device
- Direct cortical stimulation to restore vision previously demonstrated by multiple academic groups including Brindley, Dobbins, and NIH researchers
- Clinical precedent - FDA approval recently obtained by NeuroPace for the NeuroPace RNS System, a brain cortex neurostimulation device for the treatment of epilepsy



13



# U.S. Reimbursement



- Argus II candidates are primarily Medicare Beneficiaries
- In the U.S. many reimbursement objectives have been met:
  - Medicare codes for the device and surgical procedure (CPT, ICD-9-CM, HCPCS)
  - Transitional pass-through payment from Medicare for the device
  - Coverage with Palmetto and several Medicare Advantage & Commercial payers



VA, NC, SC, WV	Palmetto Medicare	Covered
U.S.	Health Net	Covered
PA, NJ, WV	Ameri-Health	Covered
PA	Independ-ence Blue Cross	Covered
AR	BCBS of Arkansas	Covered
MI	Priority Health (MA)	Covered
FL	AV Med	Covered
MN	Medica (MA)	Covered under HUD; PA req'd
MI	BCBS of Michigan (MA)	PA covered

MI	Humana (MA)	PA covered	14
IL	Humana (PPO)	PA covered	
CA	Cigna (PPO)	PA covered	
CA	Kaiser-SC	OON Coverage	
NC	Humana (MA)	PA covered	
NC	Group Health (MA)	ALJ	
NY	Emblem Health	PA covered	
TX	BCBS (MA)	PA covered	
TX	MA OON*	PA covered	
FL	Wellcare (MA)	PA (OON) covered	

# European Reimbursement

Nasdaq: EYES



- Currently in place
- In process (12 - 24 months)
- In process (24+ months)
- Not yet sought

# Implanting Centers Worldwide

Nasdaq: EYES



- North America – 11 centers; in discussions with 12 more
- EU/Middle East – 12 centers; in discussions with 13 more
- Asia partnerships anticipated as technology platform matures

North America	Germany	France
Kellogg – Univ. Michigan	University Aachen	CHU Bordeaux
Univ. Southern California	University Cologne	CHU Strasbourg
Toronto Western Hospital	University Hamburg	CHNO des XV-XX (Paris)
Wills Eye – Philadelphia	University Lübeck	
Duke Eye Center	City Karlsruhe	
Texas Retina Assoc. – Dallas	Clinic Sulzbach	
Bascom Palmer–Univ. Miami		
Wilmer – Johns Hopkins		
Emory University		
Univ. Illinois Chicago		
Mayo Clinic – Minnesota		
	Saudi Arabia	
	King Khaled Eye Specialist Hospital	
		Italy
		Firenze
		Camposanpiero (Venice)

16



- State of the art manufacturing facility located in Sylmar, California
- 10,000 square feet of controlled environment rooms (CERs).
- Current capacity: ~1200 units / year

## 10 devices / month


- Current manufacturing capacity
- Utilizing half the space
- Current staff level

Scale up to

## 100 devices / month

- Same manufacturing facility
- Utilizing the full space
- Additional staff
- Using two full shifts


17





Large portfolio creates significant barriers to entry





**We solved five very difficult technical problems that to our knowledge no other company has solved. Our patent portfolio contains a large number of claims covering these solutions:**



# Competitive Landscape



## Dominant industry position for the foreseeable future

	Regulatory Approval		Commercialized	Limitations
	CE	FDA		
 (Germany)	✓	✗	✗	<ul style="list-style-type: none"> <li>• Most devices reported to fail within 3-9 months post-implant</li> <li>• 8 hour surgical procedure</li> <li>• Requires clear eye optics and cannot be easily adapted to cortical stimulation</li> </ul>
 (France)	✗	✗	✗	<ul style="list-style-type: none"> <li>• Employs optical data link, requiring clear optics.</li> <li>• Cannot be easily adapted to cortical stimulation</li> </ul>
 (Japan)	✗	✗	✗	<ul style="list-style-type: none"> <li>• Current implant tested for a few months in two subjects</li> </ul>
 (Israel)	✗	✗	✗	<ul style="list-style-type: none"> <li>• No human implantation</li> </ul>

# Major Awards & Recognition

Nasdaq: EYES



20





- Restoring vision to the blind with the Argus II platform technology
- Targeting significant addressable market of over 8 million people
- Securing our market leading position with strong patent protection
- Ensuring first mover advantage as the only device with U.S. FDA approval
- Demonstrating reimbursement success in the U.S. and Europe
- Enhancing financial flexibility to execute strategic objectives with successful IPO and strong balance sheet





## **Second Sight Medical Products, Inc.**

12744 San Fernando Road  
Building 3

Sylmar, CA 91342

Direct: 818-833-5000

[www.secondsight.com](http://www.secondsight.com)

23

### **Retail Investor Relations**

Matt Hayden

Chairman

MZ North America

Direct: 949-259-4986

[Matt.Hayden@mzgroup.us](mailto:Matt.Hayden@mzgroup.us)

### **Institutional Investor Relations**

Lisa Wilson

President

In-Site Communications, Inc.

Direct: 212-452-2793

[lwilson@insitecony.com](mailto:lwilson@insitecony.com)





# Second Sight Medical Products

23

Everyone Should Have Vision™

